Viemed(US:VMD)2025-11-06 16:00Financial Performance - The company reported a revenue growth of 24% year-over-year in Q3 2025[7] - Net income attributable to Viemed was $3513000 in Q3 2025, or $009 per diluted share[7,8] - Adjusted EBITDA increased 16% year-over-year for Q3 2025, with an Adjusted EBITDA margin of 224%[7] - The company completed repurchases of 1706380 common shares for $114 million at an average price of $668 per share in Q3 2025[7] - Free cash flow for the quarter ended September 30, 2025, was $12402000[19] Operational Highlights - Vent patient growth was sustained at 9% year-over-year in Q3 2025, up 2% sequentially from Q2 2025[7] - Sleep therapy patients increased by 64% year-over-year and 21% sequentially in Q3 2025; new sleep patient starts were up 96% year-over-year, and sleep resupply patient count was up 51% year-over-year and 33% sequentially[7] - As of September 30, 2025, the company had $38 million in unfunded commitments available under its existing credit facilities[17] Revenue Mix - In Q3 2025, ventilation accounted for 49% of the service mix, while sleep accounted for 21%, oxygen for 9%, staffing for 8%, maternal for 6%, and other services for 7%[12] - Rental revenue accounted for 70% of the revenue mix, while sales accounted for 30% in Q3 2025[12] 2025 Guidance - The company projects net revenue of $271 million to $273 million[22] - Adjusted EBITDA is expected to be $60 million to $62 million, approximately 22% of net revenue[22]